The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Autor: Lauren E. Haydu, Sapna Pradyuman Patel, Adi Diab, Hussein Abdul-Hassan Tawbi, Michael A. Davies, Suhendan Ekmekcioglu, Jennifer L. McQuade, Isabella C. Glitza, Dai Ogata, Michael K. Wong, Rodabe N. Amaria
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
Cancer Research
Skin Neoplasms
Programmed Cell Death 1 Receptor
Kaplan-Meier Estimate
Gastroenterology
0302 clinical medicine
mucosal melanoma
Immune Checkpoint Inhibitors
Melanoma
Original Research
Aged
80 and over
Standard treatment
Hazard ratio
Mucosal melanoma
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Progression-Free Survival
Nivolumab
Oncology
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Female
Adult
medicine.medical_specialty
anti‐PD‐1
malignant melanoma
Antibodies
Monoclonal
Humanized
lcsh:RC254-282
03 medical and health sciences
Young Adult
Rare Diseases
Internal medicine
medicine
Confidence Intervals
Humans
Radiology
Nuclear Medicine and imaging
Aged
Retrospective Studies
L-Lactate Dehydrogenase
Proportional hazards model
business.industry
Clinical Cancer Research
Retrospective cohort study
medicine.disease
Confidence interval
acral melanoma
030104 developmental biology
Cutaneous melanoma
business
Zdroj: Cancer Medicine
Cancer Medicine, Vol 10, Iss 7, Pp 2293-2299 (2021)
ISSN: 2045-7634
Popis: Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these subtypes are relatively rare compared to cutaneous melanoma (CM). Methods This single institution, retrospective cohort study included patients with advanced AM and MM who underwent anti‐PD‐1 therapy for metastatic melanoma between 2012 and 2018. Objective responses were determined using the investigator‐assessed Response Evaluation Criteria in Solid Tumors version 1.1. Progression‐free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier method. A Cox regression analysis was performed to identify the factors associated with survival outcomes. Results Ninety‐seven patients were identified, 38 (39%) with AM and 59 (61%) with MM. The objective response rates (ORRs) were 21.0% and 15.2% in patients with AM and MM, respectively. The median PFS and OS were 3.6 and 25.7 months for AM patients, and 3.0 and 20.1 months for MM patients, respectively. Elevated serum lactate dehydrogenase (LDH) (AM: hazard ratio [HR], 0.22; 95% confidence interval [CI], 0.06–0.87; p = 0.03, MM: HR, 0.20; 95% CI, 0.08–0.53; p = 0.001) was significantly associated with shorter OS for both subtypes. Conclusions The ORR, PFS, and OS with anti‐PD‐1 therapy were poor in patients with AM and MM compared to those previously reported clinical trials for nonacral CM. High serum LDH was associated with significantly shorter OS.
Databáze: OpenAIRE
Externí odkaz: